Liu Wei, Zheng Ying, Zhang Zhenzhen, Yao Wenbing, Gao Xiangdong
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
Food Funct. 2014 Nov;5(11):2850-60. doi: 10.1039/c4fo00430b.
Sarcandra glabra (Thunb.) Nakai is a traditional Chinese herbal medicine and dietary supplement used for treating several diseases. The anti-diabetic activity of S. glabra polysaccharides is reported for the first time. The in vitro α-glucosidase inhibition assay indicated that the acidic S. glabra polysaccharide (SGP-2) has an IC50 of 87.06 ± 11.76 μg mL(-1), which was much lower than acarbose at 338.90 ± 46.86 μg mL(-1). Moreover, high fat diet (HFD) with streptozotocin (STZ) induced diabetic mice were administered SGP-2 (150, 300, or 600 mg kg(-1) per day, respectively) for 3 weeks. Postprandial blood glucose levels (PBGL), total cholesterol, triglyceride and free fatty acid levels in diabetic mice treated with SGP-2 were significantly decreased (p < 0.05) compared to those of the model group. The results of the oral glucose tolerance test (OGTT) and the homeostasis model assessment-insulin resistance (HOMA-IR) index indicated that SGP-2 could significantly improve (p < 0.05) the insulin resistance and glucose tolerance in diabetic mice. Furthermore, the activities of antioxidant enzymes, hexokinase and pyruvate kinase were significantly increased (p < 0.05) in SGP-2 treated groups. Thus we proposed that SGP-2 exerted hypoglycemic activity by relieving insulin resistance, reducing postprandial blood glucose levels and ameliorating lipid metabolism, as well as alleviating oxidative stress. These data suggested that SGP-2 with anti-hyperglycemic activity could be used in medicinal preparations for diabetes mellitus and its complications.
肿节风（学名：Sarcandra glabra (Thunb.) Nakai）是一种传统的中草药和膳食补充剂，用于治疗多种疾病。首次报道了肿节风多糖的抗糖尿病活性。体外α-葡萄糖苷酶抑制试验表明，酸性肿节风多糖（SGP-2）的IC50为87.06±11.76μg mL(-1)，远低于阿卡波糖的338.90±46.86μg mL(-1)。此外，给高脂饮食（HFD）联合链脲佐菌素（STZ）诱导的糖尿病小鼠分别给予SGP-2（每天150、300或600mg kg(-1)），持续3周。与模型组相比，给予SGP-2治疗的糖尿病小鼠的餐后血糖水平（PBGL）、总胆固醇、甘油三酯和游离脂肪酸水平显著降低（p<0.05）。口服葡萄糖耐量试验（OGTT）和稳态模型评估-胰岛素抵抗（HOMA-IR）指数结果表明，SGP-2可显著改善（p<0.05）糖尿病小鼠的胰岛素抵抗和葡萄糖耐量。此外，SGP-2治疗组的抗氧化酶、己糖激酶和丙酮酸激酶活性显著增加（p<0.05）。因此，我们认为SGP-2通过缓解胰岛素抵抗、降低餐后血糖水平、改善脂质代谢以及减轻氧化应激来发挥降血糖活性。这些数据表明，具有降血糖活性的SGP-2可用于糖尿病及其并发症的药物制剂中。
